A targeted research initiative to explore TRIM8 as a therapeutic target in Ewing sarcoma.
.jpg/:/)
In 2021, researchers in Dr. Kimberly Stegmaier’s laboratory at Dana-Farber Cancer Institute identified TRIM8 as a highly selective dependency in Ewing sarcoma. Their work demonstrated that TRIM8 regulates the level of EWS::FLI1, the fusion protein that drives most Ewing sarcomas. When TRIM8 is removed, EWS::FLI1 accumulates to toxic levels, causing Ewing sarcoma cells to die and significantly impairing tumor growth in laboratory models. This discovery established TRIM8 as a promising new therapeutic target. (Cancer Cell)
The project is now being advanced by Dr. Cristina Mayor-Ruiz and her research team at IRB Barcelona, in collaboration with Dr. Stegmaier’s laboratory at Dana-Farber. The immediate focus is on “enabling biochemical tractability”, developing the proteins, laboratory assays, and screening tools needed to study TRIM8 reliably and identify compounds capable of disrupting or degrading it.
This foundational work is essential for transforming an important biological discovery into a potential drug-development program. We are raising funds to support the research from its current early-discovery stage through candidate optimization, pre-clinical testing, and completion of an IND-enabling package, the studies required to support an application to begin testing a potential treatment in patients.


We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.